FORMULATION ARTICLES

FORMULATION VIDEOS

While the speed of production and flexibility of mRNA are appealing, several industry challenges must still be addressed to realize the full potential and further expand its use.

Explore an overview of the development and scale-up activities needed to develop high quality lipid nanoparticles and progress this saRNA vaccine to the clinic.

From research and clinical studies to full-scale production, revolutionize your lipid nanoparticle (LNP) production with flexible and scalable solutions.

Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their expectations on which scientific advancements/characteristics will be most important for LNP-delivery of mRNA/RNA cargo in the future.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS